Document Detail


Oral magnesium therapy improves endothelial function in patients with coronary artery disease.
MedLine Citation:
PMID:  11067788     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Magnesium blocks many of the physiological actions of calcium. Nevertheless, the impact of magnesium supplementation on endothelial function and exercise tolerance in stable coronary artery disease (CAD) patients has not been assessed. METHODS AND RESULTS: In a randomized, double-blind, placebo-controlled trial, 50 stable CAD patients (41 men and 9 women, mean+/-SD age 67+/-11 years, age range 42 to 82 years) were randomized to receive either magnesium (n=25) (30 mmol/d Magnosolv-Granulat; Asta Medica Company, Inc) or placebo (n=25) for 6 months. Before and after 6 months, endothelium-dependent brachial artery flow-mediated vasodilation (FMD) and endothelium-independent NTG-mediated vasodilation were assessed with high-resolution (10-MHz) ultrasound. Exercise stress testing was performed with use of the Bruce protocol. Intracellular magnesium concentrations ([Mg(2+)](i)) were assessed from sublingual cells through x-ray dispersion (EXA) (normal mean+/-SD values 37. 9+/-4.0 mEq/L). The magnesium therapy significantly increased postintervention ([Mg(2+)](i) versus placebo (36.2+/-5.0 versus 32.7+/-2.7 mEq/L, P<0.02). There was a significant correlation in the total population between baseline [Mg(2+)](i) and baseline FMD (r=0. 48, P<0.01). The magnesium intervention resulted in a significant improvement in postintervention FMD (15.5+/-12.0%, P=0.02 compared with baseline), which was not evident with placebo (4.4+/-2.5%, P=0.78 compared with baseline). There was better exercise tolerance (9.3+/-2.0 versus 7.3+/-3.1 minutes, P=0.05) and less ischemic ST-segment changes (4 versus 10 patients, P=0.05) in the magnesium versus placebo groups, respectively. CONCLUSIONS: Oral magnesium therapy in CAD patients is associated with significant improvement in brachial artery endothelial function and exercise tolerance, suggesting a potential mechanism by which magnesium could beneficially alter outcomes in CAD patients.
Authors:
M Shechter; M Sharir; M J Labrador; J Forrester; B Silver; C N Bairey Merz
Related Documents :
16015428 - A meta-analytic comparison of echocardiographic stressors.
3655598 - R-wave amplitude changes during exercise stress testing: patients with dilative cardiom...
1763828 - Effect of exercise training on multiple respiratory variables in patients with coronary...
3743088 - Usefulness of the ergometric testing in patients with the long q-t syndrome.
19295968 - Does creatine supplementation hinder exercise heat tolerance or hydration status? a sys...
18461208 - Dehydration rates and rehydration efficacy of water and sports drink during one hour of...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  102     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2000-11-13     Completed Date:  2000-11-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2353-8     Citation Subset:  IM    
Affiliation:
Preventive & Rehabilitative Cardiac Center and the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. shechtes@netvision.net.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Brachial Artery / drug effects,  physiology
Coronary Disease / drug therapy*
Double-Blind Method
Endothelium, Vascular / drug effects,  physiology
Exercise Tolerance / drug effects,  physiology
Female
Humans
Magnesium / pharmacology,  therapeutic use*
Male
Middle Aged
Placebos
Treatment Outcome
Vasodilation / drug effects
Chemical
Reg. No./Substance:
0/Placebos; 7439-95-4/Magnesium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoprotein...
Next Document:  Endothelial activation in patients with cardiac syndrome X.